New drug cocktail targets hard-to-treat lung cancer before surgery
NCT ID NCT07472478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a sequence of targeted therapy (garsorasib), immunotherapy (ivonescimab), and chemotherapy before and after surgery for people with a specific type of lung cancer (KRAS G12C mutation) that can be removed. The goal is to see if this approach increases the chance of no cancer remaining at surgery and delays the cancer coming back. The study plans to enroll 32 adults with stage IB to IIIB non-small cell lung cancer who have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Garsorasib (a KRAS G12C inhibitor) and ivonescimab (an immunotherapy) plus chemotherapy (paclitaxel and carboplatin)
What this could lead to
If successful, this approach could improve the chance of eliminating all cancer before surgery and delay recurrence afterward for people with this specific lung cancer mutation.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply broadly. The drug combination also carries risks of serious side effects from chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••